The success of CAR-T therapies like Bristol-Myers Squibb/Bluebird bio’s ABECMA and Janssen’s CARVYKTI is reshaping treatment paradigms, challenging traditional options like stem cell transplants and proteasome inhibitors. The multiple myeloma market size in the US is responding rapidly from ~USD 15 billion, with increased investment and innovation driving next-generation CAR-T products with improved durability, reduced toxicity, and faster manufacturing times.
As clinical research advances, CAR-T therapies are increasingly targeting earlier lines of treatment, expanding their application beyond heavily pretreated patients. This shift is being driven by promising ef...
